Who Prioritizes Innovation? R&D Spending Compared for Summit Therapeutics Inc. and Dynavax Technologies Corporation

Biotech Giants' R&D Spending: A Decade of Innovation

__timestampDynavax Technologies CorporationSummit Therapeutics Inc.
Wednesday, January 1, 20148458000015635076
Thursday, January 1, 20158694300023943601
Friday, January 1, 20168449300023689111
Sunday, January 1, 20176498800041006114
Monday, January 1, 20187495100051379106
Tuesday, January 1, 20196233100032705593
Wednesday, January 1, 20202860700053274000
Friday, January 1, 20213222800085352000
Saturday, January 1, 20224660000051999000
Sunday, January 1, 20235488600059471000
Loading chart...

Data in motion

Innovation in Focus: A Comparative Analysis of R&D Spending

In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Dynavax Technologies Corporation and Summit Therapeutics Inc. have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, Dynavax consistently allocated a significant portion of its resources to R&D, peaking in 2015 with a 13% increase from the previous year. However, a notable dip occurred in 2020, with spending dropping by 55% compared to 2019. In contrast, Summit Therapeutics showed a remarkable upward trend, particularly from 2020 to 2021, where R&D expenses surged by 60%, reflecting a strategic pivot towards innovation.

This data underscores the dynamic nature of R&D investment strategies, highlighting how these companies prioritize innovation to maintain competitive advantage in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025